ReviewClinical microbiology reviews1997
Progress towards development of a vaccine for amebiasis.
Review in Clinical microbiology reviews, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Evaluation of the PEJournal of immunology research · 2021Article
- Update on laboratory diagnosis of amoebiasis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Review
- Characteristics of inflammatory reactions during development of liver abscess in hamsters inoculated with Entamoeba nuttalli.PLoS neglected tropical diseases · 2018Article
- Indirect Haemagglutination Test in Comparison with ELISA for Detection of Antibodies against Invasive Amoebiasis.Journal of clinical and diagnostic research : JCDR · 2016Article
- Evaluation of the C-Terminal Fragment of Entamoeba histolytica Gal/GalNAc Lectin Intermediate Subunit as a Vaccine Candidate against Amebic Liver Abscess.PLoS neglected tropical diseases · 2016Article
- Immunization with the Entamoeba histolytica surface metalloprotease EhMSP-1 protects hamsters from amebic liver abscess.Infection and immunity · 2015Article
- Expression, purification, and evaluation of recombinant LecA as a candidate for an amebic colitis vaccine.Vaccine · 2014Article
- Evaluation of Entamoeba histolytica recombinant phosphoglucomutase protein for serodiagnosis of amoebic liver abscess.BMC infectious diseases · 2013Article
- Amebic infection in humans.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2012Review
- Progress in the research on diagnosis and vaccines in amebiasis.Tropical parasitology · 2011Article
- Intranasal immunization with Gal-inhibitable lectin plus an adjuvant of CpG oligodeoxynucleotides protects against Entamoeba histolytica challenge.Infection and immunity · 2007Article
- Geographic diversity among genotypes of Entamoeba histolytica field isolates.Journal of clinical microbiology · 2003Article
- Amebic Liver Abscess.Current treatment options in gastroenterology · 2002Article
- Drug targets and mechanisms of resistance in the anaerobic protozoa.Clinical microbiology reviews · 2001Review
- Cysteine proteinases and the pathogenesis of amebiasis.Clinical microbiology reviews · 2000Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The application of molecular biologic techniques over the past decade has seen a tremendous growth in our knowledge of the biology of Entamoeba histolytica, the causative agent of amebic dysentery and amebic liver abscess. This approach has also led to the identification and structural characterization of three amebic antigens, the serine-rich Entamoeba histolytica protein (SREHP), the 170-kDa subunit of the Gal/GalNAc binding lectin, and the 29-kDa cysteine-rich protein, which all show promise as recombinant antigen-based vaccines to prevent amebiasis. In recent studies, an immunogenic dodecapeptide derived from the SREHP molecule has been genetically fused to the B subunit of cholera toxin, to create a recombinant protein capable of inducing both antiamebic and anti-cholera toxin antibodies when administered by the oral route. Continued progress in this area will bring us closer to the goal of a cost-effective oral combination "enteric pathogen" vaccine, capable of inducing protective mucosal immune responses to several clinically important enteric diseases, including amebiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.